Posted by Michael Wonder on 04 Oct 2021
Enhertu granted breakthrough therapy designation in U.S.for patients with HER2 positive metastatic breast cancer treated with one or more prior anti-HER2 based regimens
4 October 2021 - Based on groundbreaking DESTINY-Breast03 results where Enhertu reduced the risk of disease progression or death by 72% versus trastuzumab emtansine.
The U.S. FDA has granted Enhertu (fam-trastuzumab deruxtecan-nxki) breakthrough therapy designation in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti-HER2 based regimens.
